| scholarly article | Q13442814 |
| P50 | author | Kasia A Sablik | Q88148116 |
| P2093 | author name string | Jeffrey Damman | |
| Caspar W N Looman | |||
| Michiel G H Betjes | |||
| Marian C Clahsen-van Groningen | |||
| Madelon van Agteren | |||
| P2860 | cites work | Treatment of symptomatic transplant glomerulopathy with rituximab. | Q46005396 |
| A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection | Q47292306 | ||
| Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study. | Q51002006 | ||
| Antibody-mediated rejection: New approaches in prevention and management. | Q52401610 | ||
| Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection. | Q53388675 | ||
| Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients. | Q53504304 | ||
| Transplant glomerulopathy: subclinical incidence and association with alloantibody. | Q53543179 | ||
| Cyclosporine: Five Years' Experience in Cadaveric Renal Transplantation | Q70309967 | ||
| IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up | Q84809003 | ||
| Histopathologic features of transplant glomerulopathy associated with response to therapy with intravenous immune globulin and rituximab | Q87378832 | ||
| A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 | ||
| Development and validation of a prognostic index for allograft outcome in kidney recipients with transplant glomerulopathy | Q36746647 | ||
| Induction therapy in renal transplantation : an overview of current developments | Q37025883 | ||
| Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. | Q37058039 | ||
| Banff 2011 Meeting report: new concepts in antibody-mediated rejection | Q37058043 | ||
| Transplant glomerulopathy | Q37092282 | ||
| The effect of combination therapy with rituximab and intravenous immunoglobulin on the progression of chronic antibody mediated rejection in renal transplant recipients. | Q37704938 | ||
| Desensitization protocols and their outcome | Q37858260 | ||
| Prevention and treatment of alloantibody-mediated kidney transplant rejection | Q37914943 | ||
| Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale | Q37990988 | ||
| The Revised (2013) Banff Classification for Antibody-Mediated Rejection of Renal Allografts: Update, Difficulties, and Future Considerations | Q38676925 | ||
| Current outcomes of chronic active antibody mediated rejection - A large single center retrospective review using the updated BANFF 2013 criteria | Q38729874 | ||
| Long-Term Renal Allograft Survival in the United States: A Critical Reappraisal | Q39824383 | ||
| Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. | Q39904553 | ||
| Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 | ||
| A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group | Q41439111 | ||
| Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure | Q42171636 | ||
| Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation | Q42247863 | ||
| Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause | Q43580802 | ||
| Determinants of long-term graft outcome in transplant glomerulopathy. | Q44697067 | ||
| Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions | Q45342440 | ||
| P433 | issue | 1 | |
| P921 | main subject | methylprednisolone | Q417222 |
| P304 | page(s) | 218 | |
| P577 | publication date | 2019-06-14 | |
| P1433 | published in | BMC Nephrology | Q15750891 |
| P1476 | title | Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection | |
| P478 | volume | 20 |
Search more.